The Russian Direct Investment Fund (RDIF) claimed that its Covid-19 vaccine Sputnik Light, a single dose shot or the first dose component of Sputnik V vaccine shows 70 per cent efficacy against the Delta variant of the Sars-CoV-2 virus. In people under 60 years, the vaccine is even more effective at 75 per cent, the RDIF said.
The developer of the vaccine, Gamaleya Center, has submitted an article analysing Sputnik Light's efficacy against the Delta variant, to the medRxiv preprint server for health sciences for publication this week.
Speaking to the media from Moscow, Kirill Dimitriev, CEO, RDIF, said, “Sputnik